M&A / Deals Gilead strikes again, penning $5bn deal to buy Tubulis PharmaphorumGilead has signed its third acquisition deal since the start of the year, agreeing to buy ADC specialist Tubulis for $3.15bn upfront.M&A / DealsRead full story pharminent April 7, 2026 (Last updated: April 7, 2026) Pharmaphorum Gilead has signed its third acquisition deal since the start of the year, agreeing to buy ADC specialist Tubulis for $3.15bn upfront. M&A / DealsRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: AbbVie Puts Humira on TrumpRx at Steep Discount as Tariff Threat SolidifiesNext: 219: An Interview With Dr. Natalie Truba on the Psychological Aspects of Gene Therapy Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
